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Abstract
Background: n-3 and n-6 polyunsaturated fatty acids (PUFAs) are the two major classes of PUFAs encountered in
the diet, and both classes of fatty acids are required for normal human health. Moreover, PUFAs have effects on
diverse pathological processes impacting chronic disease, such as cardiovascular and immune disease, neurological
disease, and cancer.
Aim: To investigate the effects of eicosapentaenoic acid (EPA) and arachidonic acid (ARA) on the proliferation and
apoptosis of human hepatoma cell line HepG2 after exposure to increasing concentrations of EPA or ARA for 48 h.
Moreover, in the same cells the gene expression of Fatty Acid Synthase (FAS) and 3-Hydroxy-3-Methyl-Glutaryl
Coenzyme A Reductase (HMG-CoAR) was also investigated.
Method: Cell growth and apoptosis were assayed by MTT and ELISA test, respectively after cell exposure to
increasing concentrations of EPA and ARA. Reverse-transcription and real-time PCR was used to detect FAS and
HMG-CoAR mRNA levels in treated cells.
Results: Our findings show that EPA inhibits HepG2 cell growth in a dose-dependent manner, starting from 25 μM
(P < 0.01, one-way ANOVA test and Dunnett’s post test) and exerts a statistically significant pro-apoptotic effect
already at 1 μM of EPA. Higher doses of ARA were need to obtain a statistically significant inhibition of cell
proliferation and a pro-apoptotic effect in these cells (100 μM, P < 0.01, one-way ANOVA test and Dunnett’s post
test). Moreover, a down-regulation of FAS and HMG-CoAR gene expression was observed after EPA and ARA
treatment in HepG2 cells, starting at 10 μM (P < 0.05, one-way ANOVA test and Dunnett’s post test).
Conclusion: Our results demonstrate that EPA and ARA inhibit HepG2 cell proliferation and induce apoptosis. The
down-regulation of FAS and HMG-CoAR gene expression by EPA and ARA might be one of the mechanisms for
the anti-proliferative properties of PUFAs in an in vitro model of hepatocellular carcinoma.
Introduction
Hepatocellular carcinoma (HCC) is the fifth most preva-
lent malignancy worldwide, furthermore its incidence is
rising [1,2]. In spite of recent progress in early diagnosis
and curative transplantation or resection due to surveil-
lance programs, most individuals present with advanced
disease [3]. Limited non curative treatment options exist
for such patients. Ethanol ablation, radiofrequency
ablation, transarterial chemoembolization and selective
radiation of lesions are some effective treatment options [3].
Systemic chemotherapy and other treatments such as
external radiation, interferon, tamoxifen, antiandrogenic
therapy or octreotide are ineffective and do not impact
survival [4].
Recently, Gao et al. [5] have demonstrated the in vitro
efficacy of C75, a Fatty Acid Synthase (FAS) inhibitor
that induces growth arrest in several HCC derived cell
lines, offering a promising novel therapy that explores
another frontier for hepatocellular cancer treatment, i.e.
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metabolic manipulation. In addition to chemically
synthesized compounds, much effort has been directed
to identifying endogenous mechanisms of tumor sup-
pression and, by high-throughput screening, of antican-
cer natural products. We have been studied some of
these compounds, such as genistein, n6-isopentenilade-
nosine, polyphenols of olive oil, showing to possess
anticancer properties in vitro and to modulate the action
of lipogenic enzymes, such as FAS, 3-Hydroxy-3-
Methyl-Glutaryl Coenzyme A Reductase (HMG-CoAR)
or Farnesyl Pyrophosphate Synthase [6-8]. FAS is the
key enzyme for the novo fatty acid synthesis [9]. Follow-
ing a rate limiting step catalyzed by acetyl CoA carboxy-
lase, it leads to the synthesis of palmityl CoA (a C16
long chain fatty acid). FAS is minimally expressed in
most normal human tissues except the liver and adipose
tissue, where it is expressed at high levels [10]. FAS
expression is markedly increased in several human
cancers compared with the corresponding normal tissue
and its overexpression in tumors has been associated
with a poor prognosis [11,12]. Our group has demon-
strated an up-regulation of FAS in human colorectal
cancer [13]. Enhanced FAS expression is a poor prog-
nostic factor in patients with breast, prostate, and ovar-
ian cancer, generating an intriguing paradigm that
cancers with high expression of FAS have a growth and/
or survival advantage and selective manipulation of FAS
may be novel therapeutic strategy [14].
Cancer cells seem to require an increased concentra-
tion of cholesterol and cholesterol precursors and this
requirement may be fulfilled by increased HMG-CoAR
activity. In previous study, HMG-CoAR activity was
found to be enhanced in human colorectal cancer that
did not express LDL receptors, indicating that LDL
receptors absence, which deprives colonic neoplastic
cells of exogenous sterols, is overcome by an increase in
endogenous cholesterol synthesis [15,16].
It is largely known that Polyunsaturated Fatty Acids
(PUFAs) are potent inhibitors of both enzymes, HMG-
CoAR and FAS [17-19] and they have been shown to
have tumoricidal action, in vitro and in vivo [20]. More-
over, it is widely recognized that both n-3 and n-6 play
additional roles as signaling molecules and modulators
of lipogenic enzyme gene expression in liver [21],
although epidemiological and experimental reports attri-
bute antitumor properties above all to n-3 PUFAs
[22-24]. PUFAs are natural constituents of animal and
vegetable lipids. Long-chain PUFAs may be directly con-
sumed in the diet or synthesized from their essential
fatty acid precursors, linoleic acid and alfa-linolenic acid
[25]. PUFAs have effects on diverse phathological pro-
cesses impacting chronic disease, such as cardiovascular
and immune disease, neurological disease and cancer.
Clinical studies from cardiovascular medicine, and other
disciplines have demonstrated correlations between low
n-3 PUFA levels and increased disease risk and have
shown that increasing n-3 levels by diet or supplementa-
tion may confer a variety of health benefits [26,27].
Our recent study [19] showed that eicosapentaenoic
acid (EPA) significantly inhibited HMGCoAR gene
expression and up-regulated mRNA LDL receptor in
HepG2 cells and the combined treatment with EPA and
Lovastatin enhanced the regulatory effect on gene
expression of HMGCoAR and LDL receptor in the same
cells. Moreover, we detected a synergistic effect on the
inhibition of cancer cell proliferation obtained by combi-
nation of EPA and Lovastatin.
On the basis of these experimental data and in an
effort to elucidate another aspect of PUFAs cell growth
control, here we investigated the effects of EPA and ara-
chidonic acid (ARA) on the proliferation and apoptosis
of human hepatoma cell line HepG2. Moreover, in the
same treated cells the gene expression of FAS and
HMG-CoAR was also investigated.
Materials and methods
Cell culture conditions
HepG2, a cell line derived from human liver tissue with
a well differentiated hepatocellular carcinoma, were
obtained from the ICLC ( IST, Genoa, Italy).
Cells were routinely cultured in DMEM ( Dulbecco’s
modified Eagle’s medium) supplemented with 10% FBS
(fetal bovine serum ), 100 U/ml penicillin, 100 g/ml
streptomycin, in monolayer culture, and incubated at
37°C in a humidified atmosphere containing 5% CO2 in
air. At confluence, the grown cells were harvested by
means of trypsinization and serially subcultured with a
1:4 split ratio. All cell culture components were pur-
chased from Sigma-Aldrich (Milan, Italy).
EPA and ARA treatment
To elucidate the effect of EPA and ARA on HMG-
CoAR and FAS gene expression and cell growth, HepG2
cells were plated at a density of 3 × 105 cells/5 ml of
DMEM containing 10% FBS in 60-mm tissue culture
dishes (Corning Costar Co., USA).
Separate plates were seeded for each assay and when
the cells were approximately 60% confluent were
exposed to the treatment.
To examine the response to EPA and ARA, HepG2
cells were treated for 48 h with culture medium supple-
mented with various concentrations of EPA and ARA,
separately (1, 10, 25, 50, 80 and 100 μM). Each experi-
ment included a control without EPA or ARA and a
control with the same amount of DMEM-BSA used for
dissolving the fatty acid.
Triplicate culture were set up for each compound
concentration and for control, and each experiment was
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repeated 4 times. Cell viability, determined using the
trypan blue exclusion test, always exceeded 90%.
Assessment of cell proliferation
After EPA and ARA treatment for 48 hours, the prolif-
erative response on HepG2 was estimated by colorimetric
3-(4,5 di-methylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) test. In brief, MTT stock (5 mg/ml in
medium) was added to each dish at a volume of one-
tenth the original culture volume and incubated for
2 hours at 37°C in humidified CO2. At the end of the
incubation period, the medium was removed, and blue
formazan crystal were solubilized with acidic isopropanol
(0.1 N HCl in absolute isopropanol). MTT conversion to
formazan by metabolically viable cells was monitored by
spectrophotometer at an optical density of 570 nm.
Assessment of cell apoptosis
The cytosolic DNA-histone complexes generated during
apoptotic DNA fragmentation in treated HepG2 cells
were evaluated with a cell death detection enzyme-
linked immunosorbent assay (ELISA) kit (Roche Diag-
nostic GmbH, Mannheim, Germany) following the
supplier’s instructions.
HMG-CoAR and FAS gene expression analysis
Analysis of gene expression was performed in HepG2
cells treated with 1, 10, 25, 50, 80 and 100 μM of EPA
and ARA, separately for 48 hours.
Cells were washed twice in phosphate buffered saline
(PBS) and then trypsinized and centrifuged at low
speed. The cell pellets were resuspended in 0.3 ml pure
distilled water and used for RNA extraction.
Total cell RNA was isolated with TRI-Reagent (Mol.
Res. Centre Inc. Cincinnati, USA), following the manu-
facturer’s instruction. About 2 μg total cell RNA,
extracted from both the control and treated cells, was
used for cDNA synthesis. Reverse transcription (RT)
was carried out in 20 μl of the final volume at 41°C for
60 min, using 30 pmol antisense primer (Table 1) for
analyses of the HMGCoAR, FAS and b-actin gene. The
b-actin gene was utilized as an internal control and was
chosen as a reference gene because it is a housekeeping
gene.
Real-time PCRs were performed in 25 μl final volume
containing 2 μl cDNA, master mix with SYBR Green
(iQ SYBR Green Supermix; Bio-Rad, Milan, Italy) and
sense and antisense primers for HMGCoAR, FAS and
b-actin gene (Table 1).
Real-Time PCR was carried out with iCycler Thermal
Cycler System apparatus (Bio-Rad) using the following
parameters: one cycle of 95°C for 1 min and 30 s, fol-
lowed by 45 cycles at 94°C for 10 s, 55°C for 10 s and
72C for 30 s and a further melting curve step at 55-95°C
with a heating rate of 0.5°C per cycle for 80 cycles. The
PCR products were quantified by external calibration
curves, one for each tested gene, obtained with serial
dilution of known copy number of molecules (102-107
molecules). All expression data were normalized by
dividing the amount of target by the amount of b-actin
used as internal control for each sample. The specificity
of the PCR product of each tested gene was confirmed by
gel electrophoresis.
Statistical Analysis
The significance of the differences between the control
group versus each experimental group of concentration
was evaluated with one way analysis of variance
(ANOVA) and the Dunnett’ post test. Differences were
considered significant at a 5% probability level.
Results
Our findings show that EPA inhibits HepG2 cell
growth in a dose-dependent manner, starting from
25 μM (P < 0.01, one-way ANOVA test and Dunnett’s
post test) (Figure 1a) and exerts a statistically signifi-
cant pro-apoptotic effect already at 1 μM (Figure 1b).
Higher doses of ARA were need to obtain a statistically
significant inhibition of cell proliferation and a
pro-apoptotic effect in same cells (100 μM, P < 0.01,
one-way ANOVA test and Dunnett’s post test) (Figure
1a and 1b), likely being HepG2 cells more sensitive
to EPA.
Moreover, a down-regulation of HMG-CoAR and FAS
gene expression was observed after EPA and ARA treat-
ment in HepG2 cells, starting at 10 μM (P < 0.05, one-
way ANOVA test and Dunnett’s post test) (Figure 2a
and 2b).
The exogenous administration of 1 mM mevalonate to
cells treated with PUFAs reverted the effect on
HMGCoA reductase gene expression but not on FAS
gene expression (data not shown).
Discussion
Recently, research on natural diet-based agents for anti-
cancer has been focused on activity capable of selective
or preferential elimination of cancer cells by inhibiting
cell growth and/or causing apoptosis [6-8].
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Figure 1 Panel a: Effect of increasing EPA and ARA concentrations on the conversion of MTT-tetrazolium salt in HepG2 cells and Panel
b: Apoptosis in HepG2 cells after EPA and ARA treatment. All data are the mean ± SE of four consecutive experiments. P value was
determined by ANOVA with Dunnett’ post test. *P < 0.01 versus control.
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Figure 2 EPA and ARA effects on HMG-CoAR (panel a) and FAS (panel b) mRNA levels in HepG2 cells. All data represent the mean ± SE
of four consecutive experiments. mRNA levels are expressed as ratio of the amount of gene target by the amount of b-actin. P value was
determined by ANOVA with Dunnett’ post test. *P < 0.05 versus control.
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In this study, we show that the exposure of HepG2
hepatoma cells to EPA and ARA leads to a cell growth
arrest and promote the apoptosis. The inhibition of cell
growth exerted by these PUFAs appears to be due to a
strong inhibition of gene expression of FAS and HMG-
CoAR. EPA inhibits FAS and HMG-CoAR gene expres-
sion in HepG2 cells more efficaciously than ARA,
because lower doses of EPA are able to elicit the inhibi-
tor effect. This finding suggests that both PUFAs affect
growth and viability even if with different kinetics. The
FAS and HMG-CoAR inhibition causes in the cell a
reduction of lipids, such as fatty acids, cholesterol, both
essential for the activity of cancer cells and its prolifera-
tion [13,15,16,28].
Our findings confirm the PUFAs anti-proliferative
effects and demonstrate that the antiproliferative efficacy
of EPA and ARA is due to down-regulation of lipogenic
enzyme gene expression, such as HMG-CoAR and FAS.
The efficacy in down-regulation of gene expression was
detected at the same doses for both substances, but the
cell growth inhibition and apoptosis was elicited at the
lower doses for EPA than ARA, confirming a major effi-
cacy for n-3 PUFA as anti-cancer agent.
Previous studies showed that PUFAs selectively
induced tumor cells apoptosis though the sensitivity of
various cancer cells to different fatty acids were found
to be variable depending on the type of cancer cell
being tested and the type and concentration of the fatty
acid used [29,30]. Previously, it was reported that essen-
tial fatty acids and their metabolites suppress tumor
cells growth both in vitro and in vivo, though at differ-
ent concentrations [29]. It was also opined that n-6 fatty
acids enhance tumor cell growth whereas n-3 fatty acids
are beneficial since they arrest cell growth. This differ-
ential action of n-3 and n-6 PUFAs in cancer has been
attributed to the formation of pro-inflammatory eicosa-
noids from n-6 PUFAs whereas products formed n-3
PUFAs are much less pro-inflammatory in nature [30].
Moreover, the present work shows that cell growth
inhibition of HepG2 by EPA and ARA takes place by
down-regulation of HMG-CoAR and FAS gene expres-
sion. Previous studies have revealed that PUFAs can reg-
ulate the expression of genes involved in several
metabolic pathways [17-19]. It has been established that
the lipogenic enzymes are in general regulated co-ordi-
nately at mRNA level [31,32]. Our current finding that
lipogenic enzymes such as FAS and HMG-CoAR are at
the same time and with the same dose of PUFAs down-
regulated in HepG2 cells is in agreement with this
hypothesis. Although the precise molecular mechanism
for this regulation is currently unclear, PUFAs may con-
trol lipogenic gene expression through their effects on
SREBP-dependent regulation [33]. SREBP-responsive
genes include those coding for HMG-CoAR and for
intermediates in cholesterol synthesis, as Farnesyl Piro-
phosphate Synthase, and for FAS [21]. PUFAs decreased
mRNA levels of lipogenic enzymes in rat hepatoma cells
and mouse liver, in correlation with their effects on
HMG-CoAR and FAS [24,34]. Fish oil feeding, rich in
the n-3 PUFAs, drastically decreased mRNA levels for
lipogenic enzymes in rodent liver [35].
It is also well known that several effects of PUFA are
due to their ability in activating peroxisome proliferator-
activated receptors (PPARs) as shown in human lung-
tumor cells [36].
Since elevated expression of HMG-CoAR and FAS in
malignant cells has been documented in various cancers
including breast, prostate, colon stomach, ovarian, endo-
metrial, lung and hepatocellular carcinoma, compounds
that can inhibit these enzymes in tumor cells, therefore,
may be effective as adjuvant chemoterapeutic agents.
Inhibition of cell growth and HMG-CoAR and FAS
gene expression was seen at concentrations of n-3 and
n-6 PUFAs that were an order of magnitude very low.
Dietary sources, therefore, may provide EPA and ARA
at levels sufficient to regulate lipogenic enzymes, but an
increased exogenous PUFAs administration should be
necessary to modulate carcinogenesis process. In fact,
caution must be applied when extrapolating in vitro
results into clinical practice.
In conclusion, at least in the experimental model used
throughout the present investigation, cell growth inhibi-
tion and apoptosis of hepatoma cells might be depen-
dent of the PUFA-induced down-regulation of lipogenic
enzyme gene expression, underlying a role for dietary
components in neoplastic cell growth control.
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